Welcome to our dedicated page for Monte Rosa Therapeutics SEC filings (Ticker: GLUE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Monte Rosa Therapeutics filings document a clinical-stage biotechnology company developing molecular glue degrader medicines and reporting as a Nasdaq-listed operating company. Its 8-K filings cover financial results, Regulation FD clinical disclosures, material-event updates and capital-structure matters tied to common stock and registration statements.
The company’s proxy materials disclose annual meeting proposals, director elections, auditor ratification and governance practices. Other filings address executive officer and principal accounting officer transitions, compensatory arrangements, shareholder voting matters, clinical program disclosures for MRT-8102 and MRT-2359, and risk areas associated with drug development, financing and public-company compliance.
Monte Rosa Therapeutics, Inc. Schedule 13G/A amendment reports that the Reporting Persons collectively hold 4,622,151 shares of Common Stock, representing 5.5% of the class based on 84,479,418 shares outstanding as of May 1, 2026. The holdings consist of two fund vehicles each holding 2,311,076 and 2,311,075 shares, and the reporting individual, Chen Yu, is disclosed as sharing voting and dispositive power through related general partner entities.
The filing clarifies ownership and voting/dispositive arrangements under Rule 13d-1(k)(1) and includes the reporting persons' address and organizational details. The statement notes potential shared voting and investment power among the named entities and that the Reporting Persons disclaim group status.
Monte Rosa Therapeutics, Inc. ownership amendment: Baker Bros. Advisors, Baker Bros. Advisors (GP) LLC, Julian C. Baker and Felix J. Baker filed Amendment No. 2 to report beneficial ownership positions in the issuer. The filing states 8,876,346 shares (9.99% of Common Stock) attributed to each of the named Reporting Persons and discloses 4,530,610 pre-funded warrants exercisable subject to a Maximum Percentage exercise limitation. The percentage calculations use 84,321,705 shares outstanding as of March 31, 2026.
Biotechnology Value Fund and affiliated reporting persons filed an amended Schedule 13G/A disclosing shared beneficial ownership in Monte Rosa Therapeutics common stock. As of March 31, 2026, BVF directly held 2,716,569 shares (approximately 3.4%) and BVF II held 1,986,984 shares (approximately 2.5%), with aggregate attributable positions reported up to 5,085,886 shares (approximately 6.3%) under certain entities. The filing states 80,015,667 Shares outstanding as of March 2, 2026 was used to compute percentages and describes 625,000 shares underlying pre-funded warrants exercisable at $0.0001 per share, subject to a 9.99% exercise blocker.
Monte Rosa Therapeutics reported a net loss of $44.5 million for the three months ended March 31, 2026, compared with net income of $46.9 million a year earlier. Collaboration revenue fell to $4.2 million from $84.9 million as prior-period payments were not repeated.
Research and development expense rose to $44.1 million, reflecting broader pipeline activity, while general and administrative costs increased modestly to $10.2 million. The company ended the quarter with $666.2 million in cash, cash equivalents and marketable securities and $671.2 million including restricted cash, and expects this to fund operations into 2029.
Monte Rosa Therapeutics reported a first quarter 2026 net loss of $44.5 million, compared with net income of $46.9 million a year earlier, as collaboration revenue normalized after large 2025 milestone payments. Q1 2026 collaboration revenue fell to $4.2 million from $84.9 million.
Research and development expenses rose to $44.1 million and general and administrative costs to $10.2 million, reflecting expansion of clinical and discovery programs. Cash, cash equivalents, restricted cash, and marketable securities reached $671.2 million, and the company expects this balance to fund operations into 2029 while it advances multiple Phase 2 studies and new IND filings.
Monte Rosa Therapeutics President & CEO Markus Warmuth reported an open-market sale of 5,467 shares of common stock. The shares were sold at a weighted average price of $18.922 per share, in multiple trades between $18.67 and $19.38.
After the transaction, Warmuth directly holds 600,004 shares of Monte Rosa Therapeutics. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on May 14, 2025, indicating the transaction timing was set in advance rather than being purely discretionary.
Monte Rosa Therapeutics Inc. notice of a proposed sale of Common shares under a Form 144, listing Rockefeller Capital Management as the broker and NASDAQ as the market.
The excerpt shows a RSU stock award of 21,865 shares dated 01/02/2025 with a related date 01/02/2026. It also records recent dispositions by Markus Warmuth: an entry dated 03/02/2026 with $97,974.22 and a sale on 04/14/2026 of 8,000 shares for $141,124.80.